Long-Term Efficacy of Fremanezumab in Chronic and Episodic Migraine Patients with Acute Medication Overuse at Baseline: Results of a 1-Year Study

被引：0
|
作者：
Silberstein, Stephen D. [1 ]
Ashina, Messoud [2 ]
Cohen, Joshua M. [3 ]
Seminerio, Michael J. [3 ]
Yang, Ronghua [3 ]
Ning, Xiaoping [3 ]
Ortega, Mario [3 ]
机构：
[1] Thomas Jefferson Univ, Jefferson Headache Ctr, Philadelphia, PA 19107 USA
[2] Univ Copenhagen, Copenhagen, Denmark
[3] Teva Pharmaceut, Frazer, PA USA
来源：
ANNALS OF NEUROLOGY | 2019年 / 86卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
S194
引用
收藏
页码：S76 / S76
页数：1
相关论文
共 50 条
  • [31] Long-term impact of fremanezumab on response rates, acute headache medication use, and disability in patients with chronic migraine who have failed at least one prior preventive migraine medication: results of a 1-year study
    McAllister, Peter
    Cohen, Joshua M.
    Yang, Ronghua
    Ning, Xiaoping
    Elms, Shawn
    CEPHALALGIA, 2019, 39 : 231 - 232
  • [32] Long-Term Impact of Fremanezumab on Response Rates, Acute Headache Medication Use, and Disability in Patients with Chronic Migraine Who Have Failed At least One Prior Preventive Migraine Medication: Results of a 1-Year Study
    McAllister, P.
    Cohen, J. M.
    Yang, R.
    Ning, X.
    HEADACHE, 2019, 59 : 119 - 119
  • [33] Long-Term Efficacy of Fremanezumab in Patients Who Reverted From a Chronic to an Episodic Migraine Classification
    Lipton, Richard
    Cohen, Joshua
    Yeung, Paul P.
    Yang, Ronghua
    Seminerio, Michael
    Campos, Verena Ramirez
    Singh, Rashmi Halker
    Ailani, Jessica
    NEUROLOGY, 2019, 92 (15)
  • [34] Long-Term Efficacy of Fremanezumab in Patients Who Reverted from a Chronic to an Episodic Migraine Classification
    Lipton, R. B.
    Cohen, J. M.
    Yang, R.
    Seminerio, M. J.
    Campos, V. Ramirez
    Singh, R. B. Walker
    Ailani, J.
    HEADACHE, 2019, 59 : 101 - 102
  • [35] Long-term efficacy of erenumab in chronic migraine (CM) patients with or without acute medication overuse (AMO)
    Tepper, Stewart
    Lipton, Richard
    Silberstein, Stephen
    Kudrow, David
    Ashina, Messoud
    Reuter, Uwe
    Dodick, David
    Zhang, Feng
    Cheng, Sunfa
    Mikol, Daniel
    NEUROLOGY, 2020, 94 (15)
  • [36] Long-term impact of fremanezumab on response rates, acute headache medication use, and disability in patients with episodic migraine: interim results of a 1-year study (vol 19, P5, 2018)
    Brandes, Jan L.
    Yeung, Paul P.
    Cohen, Joshua M.
    Gandhi, Sanjay K.
    Fitzgerald, Timothy
    Yang, Ronghua
    Ma, Yuju
    Aycardi, Ernesto
    JOURNAL OF HEADACHE AND PAIN, 2018, 19
  • [37] Long-term efficacy and safety of erenumab in patients with chronic migraine and acute medication overuse: A subgroup analysis
    Tepper, Stewart J.
    Lipton, Richard B.
    Silberstein, Stephen D.
    Kudrow, David
    Ashina, Messoud
    Reuter, Uwe
    Dodick, David W.
    Wang, Andrea
    Cheng, Sunfa
    Klatt, Jan
    Mikol, Daniel D.
    HEADACHE, 2023, 63 (06): : 730 - 742
  • [38] Long-Term Impact of Fremanezumab on Response Rates, Acute Headache Medication Use, and Disability in Patients with Episodic Migraine: Interim Results of a One-Year Study
    Brandes, J.
    Yeung, P. P.
    Cohen, J. M.
    Gandhi, S. K.
    Fitzgerald, T.
    Yang, R.
    Ma, Y.
    Aycardi, E.
    HEADACHE, 2018, 58 : 170 - 170
  • [39] Long-term Efficacy of Fremanezumab in Patients With Chronic or Episodic Migraine Who Were Inadequate Responders to Initial Fremanezumab Treatment
    Silberstein, Stephen D.
    Ortega, Mario
    Elms, Shawn
    Davis, Matthew
    Cohen, Joshua M.
    Seminerio, Michael
    Gross, Nick
    Blumenfeld, Andrew
    NEUROLOGY, 2021, 96 (15)
  • [40] Time Gained With Long-term Fremanezumab Treatment in Patients With Chronic and Episodic Migraine
    Marmura, M.
    Cohen, J. M.
    Ning, X.
    Campos, V. Ramirez
    Barash, S.
    Goadsby, P. J.
    CEPHALALGIA, 2021, 41 (1_SUPPL) : 174 - 174
12345